Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: West Pharmaceutical Services | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: West Pharmaceutical Services

Revenues up 2% in the quarter, partially offset by the voluntary recall of Vial2Bag

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

West Pharmaceutical Services
4Q Revenues:$422.5 million (+2%)
4Q Earnings: $52.0 million (n/a)
FY Revenues: $1.7 billion (+7%)
FY Earnings: $206.9 million (+37%)
Comments: Proprietary Products segment sales were up 2%, led by growth in Biologics and Generics market units. Pharma market sales were flat, affected by the voluntary recall of Vial2Bag due to reports of potential variable dosing associated with the Vial2Bag DC 13 mm device. High-value product (HVP) sales growth was 1%, led by NovaPure, FluroTec and Westar RU components, partially offset by the impact from the voluntary recall. Contract-Manufactured Products segment sales were up 2% with continued growth in diabetes-related diagnostic and delivery devices. During 2017, as a result of the continued deterioration of conditions in Venezuela, and continued reduced access to U.S. Dollar settlement controlled by the Venezuelan government, the Company recorded a charge of $11.1 million related to the deconsolidation of its Venezuelan subsidiary. As of April 1, 2017, the Company’s consolidated financial statements exclude the results of its Venezuelan subsidiary.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters